Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Samana Capital Reported 6% Stake in $ONXX

Samana Capital reported 6% passive stake in Onyx Pharmaceuticals Inc (ONXX) on October 24th. According to the filing, Samana Capital now possesses 3.84 million shares in ONXX. The firm’s previous position is unknown since its previous 13F filing is unavailable. ONXX had a strong path before the third quarter, and now it’s recovering from the slump in August. The stock has slightly lost 2% year to date, and is closed at $36 on October 27th.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

ONXX was in seventeen hedge funds in the second quarter, based on Insider Monkey’s hedge fund tracking list. David E. Shaw’s D E Shaw had more than 3 million shares at that time. Roberto Mignone’s Bridger Management retained 1.1 million shares. Some ther famous hedge funds such as Ken Griffin’s Citadel Investment Group and Jim Simons’ Renaissance Technologies also reported small positions in ONXX.

Samana Capital is formerly known as Ziff Asset Management. The firm is located in New York City, NY.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company. According to Yahoo! Finance, the company “engages in the development and commercialization of therapies that target the molecular mechanisms causing cancer”. It also conducts clinical trials on Nexavar for the treatment of liver, kidney, non-small cell lung, thyroid, breast, ovarian, and colorectal cancers. As of December 31, 2010, Nexavar was approved in more than 90 countries worldwide for the treatment of unresectable liver cancer and advanced kidney cancer.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!